Newsletter - August 1, 2005


Topics
 

» First newsletter

Welcome to Symmation's first newsletter. Within these newsletters, we will include information on up-and-coming projects, recently-completed projects, education whitepapers, tutorials and information we find useful in the field of molecular, scientific, & medical illustration and animation.

If for any reason, you no longer wish to receive this newsletter, you can unsubscribe from it at any time. Go to this page, type in the email address that you are receiving the newsletter to, select "unsubscribe" and click on submit. The process is instant and you will receive notification that you have been unsubscribed. If for some reason, you cannot complete this, please contact us directly. We hate SPAM and respect your privacy. Thank you!

Back to top

» Symmation releases a new molecular animation of Sildenafil (Viagra TM) binding to PDE5

We have just released a short animation that illustrates Sildenafil (ViagraTM) binding to its target protein, Phosphodiesterase type 5 (PDE5). This is a first step animation within a larger project that will show the complete mode of action of such PDE5 inhibitors. From the administration of the drug to the patient, to the signal transduction cascade, to the physiological effects of PDE5-inhibitors in a variety of patient uses, we will create a unique education tool.

View the portfolio entry and make sure to check out the animation:

Quicktime animation of Sildenafil (ViagraTM) binding to its target protein, Phosphodiesterase type 5 (PDE5)

Back to top


» New series of animations completed for Dr. Hudson of Vanderbilt University on ground-breaking work on collagen assembly

We have just wrapped up a large project for Dr. Billy G. Hudson, of Vanderbilt University. For now, we cannot show off our animations animations - but they are being used on his seminar & conference "circuit", and were just presented at the Collagen Gordon Conference in late July. Composed of three animations that dealt with Type IV collagen, with an emphasis on the NC1 domain, we illustrated in about 2 minutes of 30fps animation the assembly of Type IV collagen hexamers from monomeric chains. As soon as we can, we will show these off.

Related to this, we have created a cover illustration for the Journal of Biological Chemistry - once it's published, we'll be sure to post it as we think it is a radical looking image!

Technically speaking, we further developed out in-house XSI plugins and scripts to handle the extremely large molecules, to which we added long collagen tails to add to the scale of the molecules. Also, we got molecular surfacing working within XSI - next step is developing vertex shading based on atomic positions. If you are interested in XSI plugin/script development, feel free to contact us - we are always looking for talented individuals!

Back to top

» Version 3 of Symmation in the works

The current version of this website was conceived some time ago - to provide our clients with an online project tracking interface. With the evolution of Symmation, we are working on a new website that will incorporate some really cool new technology and online services that is sure to make an impact. We are also recruiting scientists/artists who can translate science/medicine into accurate and eye-catching imagery. If you are one of those people, be sure to let us know.

Back to top

Thank you for reading, and until next month, best regards.

Symmation Management


Unsubscribe from Symmation Newsletter:

If for any reason, you no longer wish to receive this newsletter, you can unsubscribe from it at any time. Go to this page, type in the email address that you are receiving the newsletter to, select "unsubscribe" and click on submit. The process is instant and you will receive notification that you have been unsubscribed. If for some reason, you cannot complete this, please contact us directly. We hate SPAM and respect your privacy. Thank you!


Home | Gallery | Client Testimonials | Contact Us | About Us | Links

© 2004-2008 Symmation LLC
All rights reserved.